SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · Teva is launching a multi-tranche debt offering of EUR and USD senior…

TEVA PHARMACEUTICAL INDUSTRIES LTD · 424B5 filed Sep 8, 2026 at 06:54 ET

At the news

NEUTRALIMPACT 5/10

424B5 filed Sep 8, 2026 at 06:54 ET

Teva is launching a multi-tranche debt offering of EUR and USD senior notes across five maturities (2032-2037), with proceeds intended to fund the conditional redemption of up to ~$4.5B in higher-coupon notes (6.750% 2028s, 7.875% 2029s, 7.375% 2029s, plus portions of 4.750% 2027s and 4.375% 2030s). This is a liability management refinancing that reduces near-term debt costs and extends maturities, but the offering size and final coupon rates are undisclosed in this preliminary filing. The transaction is credit-positive for bondholders (removing expensive debt) but neutral for equity holders as it does not change the fundamental business outlook or leverage trajectory beyond the refinancing math.

  • Teva is offering five series of senior unsecured notes: EUR 2033s, EUR 2036s, USD 2032s, USD 2034s, and USD 2037s.
  • Proceeds will fund conditional redemptions of up to $1.25B of 6.750% 2028 USD notes, $398M of 7.875% 2029 USD notes, €758M of 7.375% 2029 EUR notes, $450M of 4.750% 2027 USD notes, and €1.25B of 4.375% 2030 EUR notes.
  • The offering is conditioned on the redemptions, but the redemptions are not conditioned on the offering.
  • Teva had $16.65B of senior unsecured indebtedness outstanding as of June 30, 2026, and no secured debt.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access